120 results on '"Galindo Izquierdo M"'
Search Results
2. AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK
3. AB1354 SPANISH NATIONAL MULTICENTER REGISTRY OF PREGNANCY IN SYSTEMIC AUTOINMUNE RHEUMATIC DISEASES
4. AB1008 BRIDGING THE GAP BETWEEN PATIENT’S PERCEPTION ON QUALITY OF LIFE AND DISEASE ACTIVITY AND DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS
5. AB1653-PARE LACK OF AWARENESS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CONSEQUENCES ON A COHORT OF MODERATE AND SEVERE PATIENTS IN SPAIN: THE LUPUSVOICE STUDY
6. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain
7. Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España
8. Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?
9. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
10. POS0079-HPR PATIENT-REPORTED OUTCOMES MEASURES FOR SYSTEMIC LUPUS ERYTHEMATOSUS: AN EXPERT DELPHI CONSENSUS TO GUIDE IMPLEMENTATION IN ROUTINE CARE
11. OP0229 CHANGES IN THE CAUSES AND PREDICTORS OF LUPUS MORTALITY IN SPAIN THROUGH THE LAST DECADES: DATA FROM THE RELESSER REGISTRY
12. AB1677 VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY
13. POS1508 PREVALENCE OF REMISSION ACCORDING TO PHYSICIAN AND PATIENT AND LEVEL OF AGREEMENT IN A REAL-WORLD MULTICENTER LUPUS REGISTRY
14. AB0594 CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
15. AB0585 COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER)
16. PO.7.155 Study of the comorbidities present in the patients included in the registry of systemic lupus erythematosus of the spanish society of rheumatology (relesser)
17. PO.4.78 Validation analysis of the physician global assessment (PGA) scale in patients with systemic lupus erythematosus included in relesser-pros registry
18. S09.3 Changes in the causes and predictors of lupus mortality in Spain through the last decades: data from the relesser registry
19. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
20. Perioperative management of disease modifying anti-rheumatic drugs: Recommendations based on a meta-analysis
21. Manejo perioperatorio de los fármacos modificadores de la enfermedad en Reumatología: recomendaciones basadas en un metaanálisis
22. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up
23. ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)
24. ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)
25. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER)
26. POS0721 ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)
27. AB0248 INFLUENZA ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE TOFACITINIB CLINICAL PROGRAMME
28. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain
29. Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España
30. SAT0221 FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY
31. AB0428 ASSOCIATION BETWEEN GEOGRAPHIC AND CLIMATOLOGICAL CONDITIONS AND CUTANEOUS MANIFESTATIONS IN LUPUS PATIENTS FROM THE SPANISH RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSER) AND ARGENTINE RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSAR) COHORT
32. Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
33. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)
34. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
35. FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY
36. Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
37. The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity
38. HORMONE DEPENDENCE AND CANCER IN SYSTEMIC LUPUS ERYTHEMATOSUS
39. DO ALL ANTIPHOSPHOLIPID ANTIBODIES CONFER THE SAME RISK FOR MAJOR ORGAN INVOLVEMENT IN SLE PATIENTS?
40. ANTIPHOSPHOLIPID SYNDROME (APS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) LEADS TO A MORE SEVERE DISEASE
41. POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER)
42. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
43. Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
44. Protocolo diagnóstico y terapéutico de la hipertensión pulmonar en las conectivopatías
45. Síndrome de Sjögren
46. Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis
47. OP0042 Bacteremia in systemic lupus erythematosus patients from relesser registry: risk factors, clinical and microbiological characteristics and outcomes
48. VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY.
49. CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS.
50. COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.